Document is current

Article History

Received: 13 March 2019

Accepted: 10 September 2019

First Online: 21 October 2019

Ethics approval and consent to participate

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. This retrospective study was approved by the Institutional Review Board (IRB) of the National Cancer Center (IRB code: 2017–229). It was determined to be a retrospective analysis of de-identified data, and thus was determined to be exempt from requiring written informed consent.

: This manuscript contains no individual person’s data.

: NBo reports grants and personal fees from Ono, Bristol-Myers Squibb, during the conduct of the study; grants and personal fees from Taiho, Chugai, and Eli Lilly, outside the submitted work; KKa reports grants and personal fees from Ono, MSD, Astra Zeneca, Eli Lilly, and Beigene, outside the submitted work; ATa reports grants and personal fees from Taiho, Eli Lilly, Ono, Yakult, Chugai, Sumitomo Dainippon Pharma, LSK BioPartners, and Takeda, outside the submitted work; SIw reports grants and personal fees from Bristol-Myers Squibb, Eli Lilly, Eisai, Chugai, Daiichi Sankyo, Novartis, Merck Serono, Bayer, Otsuka, Taiho, and Ono, outside the submitted work. All other authors state that they have no conflicts of interest.